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Auranofin j2,3,4,6-tetra-0-acetyl-l-thio-ß-D-glucopyranosato-S)-(triethylpbosphine)gold],
a new gold comp oundfortreating rheumatoid arthritis (RA), is unique in that itproduces
its therapeutic benefit when administered by the oral route. Currently used gold
preparations (sodium aurothiomalate, aurothioglucose) must be given by injection to be
effective. Auranofin has been used in the treatment of RA patients in clinical trials, and
is comparable in efficacy to presently used injectable agents. Side effects with auranofin are
mild in, nature and result in fewer withdrawals from therapy than do injectable gold
preparations.
The use of gold compounds in treatment of rheumatoid arthritis
(RA) is well established, (1,2). Auranofin, [2,3,4,6-tetra-0-acetyl-l-
thio-ß-D-glucopyranosato-S)(triethylphosphine)gold], is a new
antiarthritic gold coordination complex with unique properties
(3,4). It is therapeutically effective when given by the oral route.









Gold is a metal with an aura of mysticism that has led to a long
history of medical applications and its use for these purposes
through the ages has been well reviewed recently in this journal by
G. Higby (GoldBull.,1982,15, (4), 130-140). As early as 2500 BC
Chinese and Arabic physicians used gold preparations in their
practice of medicine (5). Medieval physicians (e.g. Paracelsus) used
mixtures and ointments of colloidal gold for various ulcerative skin
conditions including rheumatism (6). However, it was not until
Koch, 1890 (7) that biological properties of gold compounds were
supported by experimental laboratory data.
Robert Koch at that time reported in vitro antitubercular activity
of gold cyanide at a dilution of 1:2 millions — a concentration much
too low to invoke cyanide ion as the active agent. Koch was unable
to demonstrate that gold salts exhibited antitubercular activity in
experimental animals and did not pursue their use further. Later
potassium gold chloride was reported of benefit in lupus vulgarus
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and syphilis, and sodium aurothiomalate in tuberculosis. The gold
decade (1925-1935) saw extensive use of intravenously administered
gold salts for treatment of tuberculosis (8). Antitubercular benefits
of the gold treatment proved to be non-existent and associated
severe toxicity was frequent. This resulted in a search for safer and
more effective agents. However, observations of the relieffrom joint
pain in a group of non-tubercular patients treated with sodium
aurothiomalate led Jacques Forestier to initiate a study of gold
compounds for treatment of rheumatoid arthritis (RA). In 1935
Forestier reported (9) the results of a six year study supporting the
beneficial effects of gold salts in slowing the evolution of RA. He
continued to be a champion of chrysotherapy until his death in
1979. Later double blind clinical studies by the Empire Rheumatism
Council (1961) confirmed Forestier's observations, documenting the
benefit of sodium aurothiomalate in RA. Radiological evidence of
the benefit of gold salts in RA was reported byJohn Sigler (10). He
observed that gold salts slow down and often eliminate the
progressive chronic joint changes associated with RA.
Rheumatoid Arthritis
What is RA and what differentiates it from related diseases? The
American Rheumatism Association classifies numerous disease
entities under the broad heading of rheumatic diseases (11). Most
prevalent of these is osteoarthritis (degenerative joint disease), often
associated with ageing. Following that in frequency is rheumatoid
arthritis, a progressive crippling disease of connective tissue that is
not age-selective. In the U.S.A. there are approximately 6 million
RA patients. Women account for about 75 per cent of this
population. The disease adopts a chronic course in about 75 per cent
of RA patients and becomes rapidly progressive in greater than 15
per cent of those involved. The most common onset is at 20-45 years
of age:
Diagnosis of RA is non-specific and depends upon a combination
of observations: evidence of joint involvement (visual or X-ray),  high
erythrocyte sedimentation rate, turbid synovial fluid with reduced
viscosity, abnormal immunoglobulin (rheumatoid factor). The
disease is characterised by progressive joint involvement leading to
loss of function as a result of joint fusion with newly formed bone.
The etiology and pathogenesis of RA remains unknown.
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However, events associated with the involved degenerative process
are attributed to malfunctions of the body's protective immune
system. Both humoral and cell mediated responsiveness are thought
to play a role in the chronic inflammation (12). The disease may be
initiated by some yet unidentified local inflammatory event
(antigenic, viral, bacterial or mechanical damage). The two arms of
the immune system respond in contrasting ways. Humoral
immunity (defence against bacterial and viral invasion) becomes
hyperactive leading to tissue destruction due to the production of
autoantibodies (antibodies against the bodies' own tissue). Cell
mediated immunity CMI, (defence against invading cellular
matter, invasive tumor growth) is suppressed, allowing growth of
tissue in the inflamed joints. Hyperactive humoral immunity and
suppressed CMI are thought to play major roles in the disease
processes present in RA.
Treatment of RA
Two groups of drugs are used in the treatment of RA.
Nonsteroidal antiinflammatory drugs (NSAIDS) and remission
inducing drugs (RIDS) / slow acting antiarthritic drugs (SAARDS).
NSAIDS (e.g. aspirin, indomethacin, ibuprofen, naproxen) act
symptomatically and serve to relieve pain associated with the
disease. In contrast, RIDS in many cases may slow or arrest the
progressive joint damage that occurs with RA.
The RIDS group comprises several different drug types:
antimalarial agents, immunosuppressive agents, and gold
compounds. Each of these is associated with side effect potential
that limits its clinical usage. Long term use of antimalarial agents
has the liability of producing irreversible ocular damage (13).
Immunosuppressive drugs carry the risk of inducing the growth of
malignant tumours as a result of non-selective suppression of
normal immunesurveillance (14). Traditional chrysotherapy, i.e.
gold therapy, is associated with numerous side effect potentials,-the
most severe being exfoliative dermatitis, bone marrow suppression
and nephrosis (12).
Gold compounds have been used with increasing frequency since
Forestier's report in 1935. In the United States sodium
aurothiomalate (MyochrysineR) and aurothioglucose (SolganalR)
are the major products. Both compounds must be given by
intramuscular injection to be effective. Patients must be monitored
frequently for evidence of toxic side effects.
New Developments
Several years ago SK &F embarked upon a research programme
to develop an improved form of gold therapy. Auranofin
(Ridaura't) is the result of that effort. It is unique in that it is
therapeutically effective when administered daily by the oral route.
Auranofin differs chemically from compounds in current use. It
is a lipophilic coordination complex of gold(1) stabilised by a
phosphine and a thiolate ligand. It exists as a monomolecular
species both in the solid state and in solution (15). In contrast,
conventional gold compounds have gold(I) coordinated between
two thiolate ligands. These compounds are very hydrophilic and
polymeric in solution. The lipophilic and monomolecular solution
properties of auranofin may facilitate its transport across biological
membranes and make it more readily available to modify cellular
processes, thus accounting for its oral efficacy.
Although the mechanism of auranofin is not known, it has been
shown to exhibit antiinflammatory and antiarthritic properties in
experimental laboratory models. It also can affect acute and chronic
inflammatory processes as well as cellular and immonopathologic
events involved in inflammation and tissue destruction.
In world-wide clinical trials auranofin has been used in treating
over 4 000 patients with RA. The results indicate that auranofin
given orally at a dose of 6mg per day is comparable in efficacy to
parenteral gold compounds in the treatment of RA.
In comparative studies side effects with auranofm were less severe
than those with injectable gold causing fewer therapy withdrawals.
Summary
Auranofin is a new gold compound useful in the treatment of
rheumatoid arthritis. It differs from injectable gold by being
effective on daily oral administration. This treatment regimen has
several advantages. It eliminates pain on injection and the nitritoid
reaction associated with injectable gold; it allows for more uniform
gold levels and results in a lower incidence of serious side effects
requiring withdrawal from therapy.
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